Ribociclib Succinate
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Ribociclib Succinate |
| DrugBank ID | DB11730 |
| Brand Names (EU) | Kisqali |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.35% |
Approved Indication (EMA)
Early breast cancerKisqali in combination with an aromatase inhibitor is indicated for the adjuvant treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer at high risk of recurrence (see section 5.1 for selection criteria).In pre- or perimenopausal women, or in men, the aromatase inhibitor should be combined with a luteinising hormone-releasing hormone (LHRH) agonist.Advanced or metastatic breast cancerKisqali is in
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | myeloid leukemia | 99.35% | DL |
| 2 | thrombocytopenia | 99.27% | DL |
| 3 | marcothrombocytopenia with mitral valve insufficiency | 99.08% | DL |
| 4 | hereditary thrombocytopenia with normal platelets | 99.07% | DL |
| 5 | transient neonatal thrombocytopenia | 98.98% | DL |
| 6 | dense granule disease | 98.90% | DL |
| 7 | female breast carcinoma | 98.47% | DL |
| 8 | multiple endocrine neoplasia | 98.10% | DL |
| 9 | HIV infectious disease | 98.09% | DL |
| 10 | heart neoplasm | 98.07% | DL |
| 11 | platelet storage pool deficiency | 97.94% | DL |
| 12 | plasma cell myeloma | 97.72% | DL |
| 13 | collagenopathy | 97.69% | DL |
| 14 | lymphocytic hypereosinophilic syndrome | 97.66% | DL |
| 15 | cardiovascular disease | 97.57% | DL |
| 16 | heart valve disease | 97.56% | DL |
| 17 | simian immunodeficiency virus infection | 97.55% | DL |
| 18 | feline acquired immunodeficiency syndrome | 97.55% | DL |
| 19 | heart conduction disease | 97.50% | DL |
| 20 | melanoma | 97.47% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.